




>>Entry Name: Temozolomide, BAN, INN, USAN

Synonym(s): 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-*d*][1,2,3,5]tetrazine-8-carboxamide, 9Cl. Methazolastone. Temodal. Temodar. CCRG 81045. M



CAS Registry Number: 85622-93-1

Molecular Formula: C₆H₆N₆O₂

Molecular Weight: 194.152

Accurate Mass: 194.055224

Percentage Composition: C 37.12%; H 3.11%; N 43.29%; O 16.48%

Biological Use/Importance: Antineoplastic agent. Used for the treatment of glioblastoma multiforme

Physical Description: Light brown solid

Development Status: Launched 1999 (UK). Approved for clinical use in the EU (1999)

Melting Point: Mp 210-212 dec.°

Calculated Log P Data: Log P -1.16 (uncertain value) (calc)

Hazard & Toxicity: LD_{Lo} (mus, ipr) 125 mg/kg

References:

- U.K. Pat., 1983, *May and Baker*, 2 104 522; *CA*, **98**, 198285m, (*synth*)
Stevens, M.F.G. *et al.*, *J. Med. Chem.*, 1984, **27**, 196, (*synth, ir, pmr*)
Tisdale, M.J., *Br. J. Cancer*, 1985, **52**, 789, (*pharmacol*)
Bull, V.L. *et al.*, *Biochem. Pharmacol.*, 1987, **36**, 3215, (*pharmacol*)
Stevens, M.F.G. *et al.*, *Cancer Res.*, 1987, **47**, 5846, (*synth, pharmacol, pharmacokinet, pmr*)
Tsang, L.L.H. *et al.*, *Cancer Chemother. Pharmacol.*, 1990, **26**, 429, (*metab*)
Newlands, E.S. *et al.*, *Br. J. Cancer*, 1992, **65**, 287, (*clin trial*)
Lowe, P.R. *et al.*, *J. Med. Chem.*, 1992, **35**, 3377, (*cryst struct*)
Denny, B.J. *et al.*, *Biochemistry*, 1994, **33**, 9045, (*pmr*)
Wang, Y. *et al.*, *Chem. Comm.*, 1994, 1687-1688, (*synth*)
Wheelhouse, R.T. *et al.*, *J.C.S. Perkin I*, 1995, 249, (*cmr, N-15 nmr*)
Newlands, E.S. *et al.*, *Cancer Treat. Rev.*, 1997, **23**, 35
Wang, Y. *et al.*, *J.O.C.*, 1997, **62**, 7288-7294, (*synth*)
Hvizdos, K.V. *et al.*, *CNS Drugs*, 1999, **12**, 237, (*rev*)
Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 565